1-3 of 3
Ferran Fece de la Cruz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma

Qibiao Wu, Haley Ellis, Giulia Siravegna, Alexa G. Michel, Bryanna L. Norden, Ferran Fece de la Cruz, Eranga Roshan Balasooriya, Yuanli Zhen, Vanessa S. Silveira, Jianwe Che, Ryan B. Corcoran, Nabeel Bardeesy
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 198–208.
https://doi.org/10.1158/1078-0432.CCR-23-1317
Published: 05 January 2024
View article titled, Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
Open the PDF for Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition

Meagan B. Ryan, Ferran Fece de la Cruz, Sarah Phat, David T. Myers, Edmond Wong, Heather A. Shahzade, Catriona B. Hong, Ryan B. Corcoran
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (7): 1633–1643.
https://doi.org/10.1158/1078-0432.CCR-19-3523
Published: 01 April 2020
View article titled, Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS<sup>G12C</sup> Inhibition
Open the PDF for Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS<sup>G12C</sup> Inhibition in another window
Includes: Supplementary data
Journal Articles

Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

Julia K. Rotow, Philippe Gui, Wei Wu, Victoria M. Raymond, Richard B. Lanman, Frederic J. Kaye, Nir Peled, Ferran Fece de la Cruz, Brandon Nadres, Ryan B. Corcoran, Iwei Yeh, Boris C. Bastian, Petr Starostik, Kimberly Newsom, Victor R. Olivas, Alexander M. Wolff, James S. Fraser, Eric A. Collisson, Caroline E. McCoach, D. Ross Camidge, Jose Pacheco, Lyudmila Bazhenova, Tianhong Li, Trever G. Bivona, Collin M. Blakely
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (2): 439–449.
https://doi.org/10.1158/1078-0432.CCR-19-1667
Published: 15 January 2020
View article titled, Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer
Open the PDF for Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer in another window
Includes: Supplementary data